EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 36 (Décembre 2020) Hors série n° 2 Med Sci (Paris), 36 (2020) 17-21 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 36, Décembre 2020
Les Cahiers de Myologie
Page(s) 17 - 21
Section Dystrophies musculaires des ceintures (LGMD)
DOI https://doi.org/10.1051/medsci/2020244
Publié en ligne 11 janvier 2021
  1. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995 ; 81 : 27–40. [CrossRef] [PubMed] [Google Scholar]
  2. Duguez S, Bartoli M, Richard I. Calpain 3: a key regulator of the sarcomere?. FEBS J 2006 ; 273 : 3427–3436. [CrossRef] [PubMed] [Google Scholar]
  3. Kinbara K, Sorimachi H, Ishiura S. Suzuki K Muscle-specific calpain, p94, interacts with the extreme C-terminal region of connectin, a unique region flanked by two immunoglobulin C2 motifs. Arch Biochem Biophys 1997 ; 342 : 99–107. [CrossRef] [PubMed] [Google Scholar]
  4. Sorimachi H, Kinbara K, Kimura S, et al. Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 1995 ; 270 : 31158–31162. [CrossRef] [PubMed] [Google Scholar]
  5. Fardeau M, Hillaire D, Mignard C, et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996 ; 119 : 295–308. [CrossRef] [PubMed] [Google Scholar]
  6. Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC consortium on limb-girdle dystrophies. Neuromuscul Disord 1995 ; 5 : 71–74. [CrossRef] [PubMed] [Google Scholar]
  7. Straub V, Murphy A, Udd B, group Lws. 229th ENMC international workshop: limb girdle muscular dystrophies. Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul Disord 2018; 28 : 702–10. [CrossRef] [PubMed] [Google Scholar]
  8. Vissing J, Barresi R, Witting N, et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain 2016 ; 139 : 2154–2163. [CrossRef] [PubMed] [Google Scholar]
  9. Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Trans Neurol 2018 ; 5 : 1574–1587. [CrossRef] [Google Scholar]
  10. Gonzalez-Mera L, Ravenscroft G, Cabrera-Serrano M, et al. Heterozygous CAPN3 missense variants causing autosomal-dominant calpainopathy in seven unrelated families. Neuropathol Appl Neurobiol 2020; Sep 8. doi: 10.1111/nan.12663. [Google Scholar]
  11. Vissing J, Dahlqvist JR, Roudaut C, et al. A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. Hum Mutat 2020; 41 : 1507–13. [PubMed] [Google Scholar]
  12. Cerino M, Campana-Salort E, Salvi A, et al. Novel CAPN3 variant associated with an autosomal dominant calpainopathy. Neuropathol Appl Neurobiol 2020; 46 : 564–78. [CrossRef] [PubMed] [Google Scholar]
  13. Lostal W, Urtizberea JA, Richard I. 233rd ENMC International workshop: clinical trial readiness for calpainopathies, Naarden, The Netherlands, 15–17 September 2017. Neuromuscul Disord 2018 ; 28 : 540–549. [CrossRef] [PubMed] [Google Scholar]
  14. Richard I, Hogrel JY, Stockholm D, et al. Natural history of LGMD2A for delineating outcome measures in clinical trials. Ann Clin Trans Neurol 2016 ; 3 : 248–265. [CrossRef] [Google Scholar]
  15. Keira Y, Noguchi S, Kurokawa R, et al. Characterization of lobulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling. Neurosci Res 2007 ; 57 : 513–521. [CrossRef] [PubMed] [Google Scholar]
  16. Milic A, Daniele N, Lochmuller H, et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul Disord 2007 ; 17 : 148–156. [CrossRef] [PubMed] [Google Scholar]
  17. Barp A, Laforet P, Bello L, et al. European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A). J Neurol 2020; 267 : 45–56. [Google Scholar]
  18. Bartoli M, Roudaut C, Martin S, et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 2006 ; 13 : 250–259. [CrossRef] [PubMed] [Google Scholar]
  19. Roudaut C, Le Roy F, Suel L, et al. Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy. Circulation 2013 ; 128 : 1094–1104. [CrossRef] [PubMed] [Google Scholar]
  20. Lostal W, Roudaut C, Faivre M, et al. Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A. Sci Trans Med 2019; 11 (520). [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.